Bli medlem
Bli medlem

Du är här


Nuevolution: Redeye: A good BET in Nuevolution

Nuevolution has a transforming year behind them and more updates are
expected by the end of the year. We see the BET-inhibitor program as
the most interesting from a partnering perspective and the prospects
for a licensing deal are good. Further, an additional drug discovery
collaboration deal has a good possibility of being realized. In this
new Research Update Mathias Spinnars is summing up the fiscal year
2016/17, what lies ahead and the valuation of the company. Continue
reading at:

Start following companies at Redeye to receive the latest equity
research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment


Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.